Survodutide — Dual GLP-1/Glucagon for MASH + Diabetes

Type: drug

Status: Active trial

Developer: Boehringer Ingelheim

Breakthrough Summary

Dual GLP-1/glucagon receptor agonist showing remarkable efficacy in patients with both MASH (fatty liver) and Type 2 diabetes. Phase 3 results expected mid-2026.

Mechanism of Action

Dual GLP-1/glucagon receptor agonist addressing the liver-pancreas axis

Year: 2025-2026